Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

LX9211 · BMS-986176

Small molecule · developed by Lexicon Pharmaceuticals

Phase 2 Most advanced trial (none active)

LXRX Developer

2 Registered trials

What is LX9211?

LX9211 is an investigational small-molecule drug studied in Postherpetic Neuralgia, Diabetic Peripheral Neuropathic Pain.

At a glance

Also known as: BMS-986176
Drug type: Small molecule
Therapy area: Neurology
Developer: Lexicon Pharmaceuticals (LXRX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: 9G4RLM5X6Z

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06203002	Phase 2	Diabetic Peripheral Neuropathic Pain	Completed	LXRX
NCT04662281	Phase 2	Postherpetic Neuralgia	Completed	LXRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Diabetic Peripheral Neuropathic PainPostherpetic Neuralgia

More from Lexicon Pharmaceuticals

Sotagliflozin FDA approved LX7101 Phase 1/2 Octreotide LAR Depot Phase 2

Sources

ClinicalTrials.gov NCT04662281

Updated Oct 3, 2026. Something wrong or missing? Report it on the LXRX page.

Follow LXRX, the company behind LX9211

See LXRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LXRX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z